发明名称 Rho kinase inhibitors
摘要 The present invention relates to compounds of formula (I):; and pharmaceutically acceptable salts thereof, wherein R1, R2, R3 and X are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
申请公布号 US9000154(B2) 申请公布日期 2015.04.07
申请号 US201113274610 申请日期 2011.10.17
申请人 Boehringer Ingelheim International GmbH 发明人 Kirrane Thomas Martin;Marshall Daniel Richard;Sibley Robert;Snow Roger John;Soleymanzadeh Fariba;Sorcek Ronald John
分类号 C07D417/14;A61K31/5355;C07D417/12;C07D277/60 主分类号 C07D417/14
代理机构 代理人 Morris Michael P.;Lazer Edward S.
主权项 1. A compound of the formula I wherein: X is selected from the group Xa consisting of A is C or N; Y is O or S; R1 is selected from the group R1a consisting of R2 and R3 are independently selected from H, —CH3, —OCH3, —F, —Cl, —C(O)NH2, and —CN, provided that R2 and R3 are not both H; R4 is H or —CH3; R5 is C1-6alkyl; R6 is selected from a heterocyclyl group selected from piperidinyl, piperazinyl, morpholinyl, 2,3-dihydroindolyl and pyrrolidinyl, and —N(R7)(R8), wherein the heterocyclyl group may be substituted with one to three groups selected from halogen, oxo, C1-3alkyl and C3-6cycloalkyl; R7 and R8 are independently selected from H, C1-3alkyl, C3-6cycloalkyl and CO2C1-4-alkyl, wherein the C1-3alkyl and C3-6cycloalkyl are optionally substituted with —OCH3, —CF3, —CHF2 or —CN; and n is 1 or 2; or a salt thereof.
地址 Ingelheim am Rhein DE